|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Identical BRAF V600E and telomerase reverse transcriptase promoter mutations were identified in both the original and recurrent tumor.
|
29620581 |
2019 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The primary and recurrent tumors both harbored the BRAF V600E mutation, and the recurrent tumor was immunonegative for ATRX.
|
28185325 |
2017 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The tumor showed necrosis and the BRAF V600E mutation on histological examination, with no evidence of tumor recurrence 1 year after gross-total resection.
|
27015517 |
2016 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
TERT promoter mutations are associated with aggressive thyroid tumor characteristics, tumor recurrence and patient mortality as well as BRAF V600E mutation.
|
26733501 |
2016 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The aim of the present study was to clarify the association between c-MET expression and tumor recurrence in CRC patients after curative liver resection, and to evaluate concordance in c-MET expression and various mutations of KRAS, BRAF and PIK3CA between primary CRC and paired liver metastases.
|
24863535 |
2014 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Tumor recurrence rates were 25.8% (50 of 194;77.60 recurrences per 1,000 person-years; 95% CI, 58.81 to 102.38) versus 9.6% (30 of 313; 22.88 recurrences per 1,000 person-years; 95% CI, 16.00 to 32.72) in BRAF mutation-positive versus -negative patients (hazard ratio [HR], 3.22; 95% CI, 2.05 to 5.07) and 47.5% (29 of 61; 108.55 recurrences per 1,000 person-years; 95% CI, 75.43 to 156.20) versus 11.4% (51 of 446; 30.21 recurrences per 1,000 person-years; 95% CI, 22.96 to 39.74) in TERT mutation-positive versus -negative patients (HR, 3.46; 95% CI, 2.19 to 5.45).
|
25024077 |
2014 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Decreased CPSF2 gene expression was associated with shorter disease-free survival (P = .03), large tumor size (T3 and T4) (P = .03), tumor recurrence (P < .01), and mortality (P < .01), independent of BRAF V600E mutation status.
|
24654752 |
2014 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Although multivariate analysis showed that tumor recurrence was not associated with BRAF(V600E) mutation, it has not been shown that treating these patients more aggressively changes outcomes.
|
23370668 |
2013 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
Genetic analyses revealed amplification of the BRAF gene in both the primary cerebellar pilocytic astrocytoma and the recurrent tumor with biphasic features, as well as a BRAF V600E missense mutation in the oligodendroglioma-like component.
|
23082883 |
2013 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
The proportion of BRAF(V600E) mutation was significantly associated with the number of high-risk factors of tumor recurrence (P < 0.001).
|
22190222 |
2012 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
We investigated the usefulness of defective mismatch repair (dMMR), BRAF, and KRAS mutations in predicting tumor recurrence and sensitivity to chemotherapy.
|
21383284 |
2011 |
|
Recurrent tumor
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
These miRNAs were further validated by real-time RT-PCR in a cohort of 17 PTC with local tumor recurrence or distant metastases and 15 PTC with no extrathyroidal dissemination and correlated with BRAF, RAS, and RET/PTC mutations and MET expression.
|
21537871 |
2011 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
In addition to the diagnostic use, BRAF V600E mutation can also be used for tumor prognostication, as this mutation is associated with higher rate of tumor recurrence and tumor-related mortality.
|
21526955 |
2011 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To date, a mutation of the BRAF oncogene is the most common genetic alteration found in papillary thyroid carcinoma (PTC) and is associated with extrathyroidal extension, lymph node metastasis, and tumor recurrence.
|
19958951 |
2009 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
There was a statistically significant association between the BRAF mutation and recurrent tumor (P = 0.003).
|
17962436 |
2007 |
|
Recurrent tumor
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
BRAF mutation was also significantly associated with tumor recurrence, 25 vs. 9% with and without mutation, respectively (P = 0.004), during a median of 15 (interquartile range, 3-29) months of follow-up.
|
16174717 |
2005 |